[新型抗癌疗法的眼科毒性]
Rafael Boucher1, Matthieu Delaye2, Oscar Haigh3
1Service d'ophtalmologie, CHU de Bicêtre, Assistance publique, Hopitaux de Paris, Université Paris Saclay, Le Kremlin Bicêtre, France.
Bulletin du cancer
|March 19, 2025
概括
现代抗癌疗法,包括免疫检查点抑制剂 (ICI),抗体药物联合体 (ADC) 和向抗癌疗法 (TAT),可以引起各种眼部不良事件 (OAEs). 瘤学家和眼科医生的早期诊断和管理对于患者的视力和生活质量至关重要.
科学领域:
- 眼科医生 眼科 眼科
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 现代抗癌疗法 (MAT) 提供有针对性的治疗,毒性降低.
- 这些药物包括免疫检查点抑制剂 (ICI),抗体药物合剂 (ADC) 和向抗癌疗法 (TAT).
- 这些疗法与一系列的眼部不良事件 (OAEs) 相关,从轻微的刺激到严重的视力丧失.
研究的目的:
- 审查与MAT相关的OAE的临床特征.
- 描述这些OAE的疑似病理生理机制.
- 在接受MAT的患者中概述OAE的关键管理策略.
主要方法:
- 关于OAEs的临床特征,机制和管理的文献综述.
- 对ICI,ADC和TAT特有的OAE的分析.
- 对新型抗癌剂对眼睛的毒性现有知识的综合.
主要成果:
- ICI可以诱导影响所有眼睛组织的自身免疫性OAEs.
- ADCs通常会导致眼睛表面的毒性,特别是微囊状上皮细胞变化 (MECs).
- TAT 呈现出不同的 OAEs,这取决于它们的特定分子点.
结论:
- 眼部不良事件是现代抗癌疗法的一个重大问题.
- 了解特定的OAE及其机制对于有效管理至关重要.
- 瘤学家和眼科医生的合作对于最佳的患者护理和视觉结果至关重要.
相关概念视频
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Open Angle Glaucoma: Treatment
378
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
378
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
145
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
145
Tumor Immunotherapy
454
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
454
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
170
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
170


